TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Licia Rivoltini1, Claudia Chiodoni2, Paola Squarcina1, Monica Tortoreto3, Antonello Villa4, Barbara Vergani4, Maja Bürdek1, Laura Botti3, Ivano Arioli2, Agata Cova1, Giorgio Mauri2, Elisabetta Vergani3, Beatrice Bianchi1, Pamela Della Mina4, Laura Cantone5, Valentina Bollati5, Nadia Zaffaroni3, Alessandro Massimo Gianni6, Mario Paolo Colombo2, and Veronica Huber1

Abstract

Purpose: Exosomes deliver signals to target cells and could thus be exploited as an innovative therapeutic tool. We investigated the ability of membrane TRAIL–armed exosomes to deliver proapoptotic signals to cancer cells and mediate growth inhibition in different tumor models.

Experimental Methods and Results: K562 cells, transduced with lentiviral human membrane TRAIL, were used for the production of TRAIL−exosomes, which were studied by nanoparticle tracking analysis, cyttofluorimetry, immunoelectronmicroscopy, Western blot, and ELISA. In vitro, TRAIL−exosomes induced more pronounced apoptosis (detected by Annexin V/propidium iodide and activated caspase-3) in TRAIL-death receptor (DR)5+ cells (SUDHL4 lymphoma and INT12 melanoma), with respect to the DR5−DR4−KMS11 multiple myeloma. Intratumor injection of TRAIL−exosomes, but not mock exosomes, induced growth inhibition of SUDHL4 (68%) and INT12 (51%), and necrosis in KMS11 tumors. After rapid blood clearance, systemically administered TRAIL−exosomes accumulated in the liver, lungs, and spleen and homed to the tumor site, leading to a significant reduction of tumor growth (58%) in SUDHL4-bearing mice. The treatment of INT12-bearing animals promoted tumor necrosis and a not statistically significant tumor volume reduction. In KMS11-bearing mice, despite massive perivascular necrosis, no significant tumor growth inhibition was detected.

Conclusions: TRAIL−armed exosomes can induce apoptosis in cancer cells and control tumor progression in vivo. Therapeutic efficacy was particularly evident in intratumor setting, while depended on tumor model upon systemic administration. Thanks to their ability to deliver multiple signals, exosomes thus represent a promising therapeutic tool in cancer.

Clin Cancer Res; 22(14); 3499–512. ©2016 AACR.
translated proteins and cargo (19). Although exosomes have been found to contain a multitude of apparently randomly assembled proteins and RNAs, their content is the result of a selective molecule-driven sorting, that only recently is starting to be elucidated (20). Once secreted into the extracellular milieu by fusion of the MVEs with the plasma membrane, exosomes can interact with recipient cells by receptor-ligand docking, fusion, or endocytosis (17). Cancer has been representing a crucial necessity/maintenance of infection tested by fluorescence microscopy (11). The INT12 melanoma cell line was generated in our laboratory from a human melanoma specimen. Mycoplasma contamination was tested periodically. Cell lines were maintained in RPMI-1640 medium supplemented with 10% FCS, 2 mmol/L L-glutamine, and 200 U/mL penicillin/streptomycin.

Lentiviral vector construction and transduction of exosome-producing cells

Membrane-bound TRAIL-encoding lentiviral vector was constructed replacing the GFP sequence of pCCL.sin.PPT.hPGK.GFP.pre (kind gift from L. Naldini, HSR, Italy) with human mTRAIL (NM_003810) coding sequence to produce the lentiviral vector or with ANGFR (kind gift from G. Ferrari, HSR, Italy), a truncated nerve growth factor receptor (NGFR) sequence, to produce the control lentiviral vector, lenti-NGFR. The viral stocks were prepared using standard methods (29). Infection was performed at different MOI, in presence of 8 μg/mL of polybrene. After 24 hours, the medium was replaced and efficiency/maintenance of infection tested by flow cytometry after 24 hours and 14 days.

Exosome isolation and nanoparticle tracking analysis

The supernatant of 10^5 K562 cells TRAIL+ or NGFR+, cultured 24 hours in serum-free RPMI-1640 medium, was sequentially diluted at 300 x g (10 minutes), 4,000 x g (20 minutes), 0.22-μm vacuum filtered (Millipore) to eliminate larger EVs and ultracentrifuged (Thermo Fisher Scientific) at 100,000 x g (4 hours) at 4°C. Exosomes were washed/concentrated in PBS at 100,000 x g (1 hour) at 4°C, suspended in PBS and after protein determination (Bradford Protein Assay; Bio-Rad), frozen at −80°C (200 and 400 μg aliquots). To minimize interpereation variability, exosomes were routinely checked by nanoparticle tracking analysis (NTA), immunoelectronmicroscopy (TRAIL and exosomal markers), and ELISA. Viability, phenotype, and cytokine release of K562 TRAIL+ cells cultured in the absence of FCS for exosome production was comparable with those cultured in complete medium (Supplementary Fig. S1A–S1C). The size and quantity of purified TRAIL exosomes (5 μg; diluted 1:10,000) was determined using a LM10-HS NanoSight instrument and NTA.
software (NanoSight). Preparations were analyzed five times for 30 seconds.

**Electron and confocal microscopy**

For routine staining of exosomes, preparations, fixed with 4% paraformaldehyde and deposed on Formvar-carbon-coated Nickel grids, were incubated with anti-TRAIL Ab (1:5) or anti-CD63, LAMP-2 (BD Pharmingen), and Rab 5B (1:10) Mix Abs, followed by gold-conjugated goat anti-mouse IgG (H+L) 6 nm and goat anti-rabbit IgG (H+L) 5 nm Abs (Jackson ImmunoResearch) and examined by transmission electron microscope CM 10 Philips (FEI). For confocal microscopy, frozen tissue sections tissues (6 μm) were evaluated by a Radiance 2100 microscope (Bio-Rad Laboratories).

**Western blot and ELISA**

Standard Western blot analysis was performed using 4% to 12% bis-Tris precast gels (Invitrogen), nitr cellulose membranes (Amersham), and enhanced chemiluminescence (SuperSignal). Exosomal TRAIL was quantified by ELISA (Human TRAIL, Quantikine; R&D Systems), according to the manufacturer’s instructions, without applying the lysing procedure.

**Flow cytometry**

Flow cytometry of cells was performed according to standard procedures. Flow cytometry of exosomes was performed using sulfate/aldehyde latex beads (5 μm; Life Technologies; ref. 30). Apoptosis was detected by Annexin V/propidium iodide (PI) staining, performed according to the manufacturer’s instructions (Annexin V-FITC Apoptosis Detection Kit; Bender MedSystems GmbH). Activated caspase-3 was detected in permeabilized cells. Samples were evaluated using a FACS-Calibur flow cytometer (BD Biosciences) and the FlowJo software (TreeStar Inc.).

**In vivo studies**

Mice were maintained at the Fondazione IRCCS Istituto Nazionale dei Tumori under standard conditions according to institutional guidelines. All procedures were approved by the Institute Ethical Committee for animal use and by the Italian Ministry of Health. A total of 20 × 10⁶ SUDHL4 cells were subcutaneously xenotransplanted into 8-week-old female NOD-SCID mice. Treatments were started when tumors reached 100 mm³. If not otherwise specified, the treatment schedule consisted in 4 injections, every 48 hours, of 200 μg/injection of TRAIL or NGFR exosomes, sTRAIL (intra-tumor: 200 ng or 300 μg/injection; i.v.: 30 mg/kg/injection) or saline. Mice were sacrificed 24 hours after the last treatment or during follow-up at the first signs of distress and lesions and organs collected. TV was measured by Vernier caliper. For the KMS11 model, cells were injected subcutaneously to 8-week-old female NOD-SCID for matrigel and growing tumors and later distinguished between Matrigel and growing tumors and later measured by Vernier caliper. For the KMS11 model, cells were injected subcutaneously to 8-week-old female NOD-SCID for intravenous treatments and SCID mice for intratumor treatments. The schedule of 4 intravenous injections for systemic therapy was designed on the basis of previous experience with TRAIL-expressing CD34⁺ cells, introducing a precautionary 48 hours interval, instead of the 24 hours there used, to minimize embolic risk (34). If not otherwise specified, each experiment was performed at least two times, using 5 to 7 animals per group.

**IHC**

Formalin-fixed and paraffin-embedded tissue sections (3–4 μm) were incubated with the following Abs: Ki67 (Immunological Sciences), caspase-3 (Cell Signaling Technology), and anti-human TRAIL-DR5 (Novus Biologicals), cross-reacting with mouse TRAIL-DR5. UltraVision Quanto Detection System HRP (Thermo Fisher Scientific Inc.) and DAB (Liquid DAB+ Substrate Chromogen System; Dako) were used to develop the reaction. TUNEL staining (ApopTag Peroxidase In Situ Apoptosis Detection Kit; Millipore) was performed according to the manufacturer’s instructions. Images were acquired by Aperio ScanScope XT systems (Aperio Technologies, Leica Microsystems Stil) or Eclipse 800 microscope (Nikon).

**Statistical analysis**

Data were analyzed using GraphPad Prism 5.0 Software (GraphPad Software Inc.). Results are shown as mean ± SD or SEM and analyzed using two-way ANOVA and unpaired Student t test, as specified.

**Results**

**Generation of TRAIL-expressing exosomes**

K562 cells were transduced with a lentiviral vector containing human membrane TRAIL (lenti-huPKG-TRAIL) or encoding for a human truncated non-functional NGF receptor (lenti-huPKG-NGFR) to obtain TRAIL⁺ K562 and NGFR⁺ K562 control cells (Fig. 1A and B). TRAIL⁺ K562 cells expressed no TRAIL death receptors and the stability of TRAIL expression (40 MOI) during large-scale expansion, was confirmed (Supplementary Fig. S1D–S1F). Exosomes isolated by sequential ultracentrifugation were at first evaluated by NTA technology, showing a vesicle population of 140 nm as mean size. Western blot analysis in exosome preparations, each experiment was performed at least two times, using 5 to 7 animals per group.
Figure 1.
Generation of TRAIL-expressing exosomes. A, transduction of K562 cells with human membrane TRAIL. K562 cells were infected with different MOI (5, 20, and 40) of lenti huPGK-TRAIL. Flow cytometry analysis of TRAIL expression 24 hours posttransduction and after 2 weeks of *in vitro* culture. K562 lenti-TRAIL 40 MOI cells were chosen for subsequent studies. B, transduction of K562 cells with human NGFR. K562 cells were infected with different MOI (10 and 30) of lenti-NGFR. Flow cytometry analysis of NGFR expression 24 hours posttransduction and after 2 weeks of culture. K562 lenti-NGFR 30 MOI cells were chosen for subsequent studies. C, characterization of TRAIL exosomes. Assessment of size, number, and distribution of TRAIL exosomes by NTA technology. D and E, flow cytometry of exosome-bead complexes for the expression of TRAIL and CD63 on purified TRAIL exosomes and NGFR and CD63 on purified NGFR exosomes. Filled histograms represent the positivity for molecule tested, lines represent IgG controls. F, electronmicroscopy of exosomes purified from conditioned media of TRAIL-transduced K562 cells. G and H, immunoelectronmicroscopy of TRAIL exosomes labeled for TRAIL and CD63, Rab 5B, and Lamp-2 exosomal markers. I, Western blot analysis of TRAIL exosomes and originating K562 TRAIL+ cells for the expression of membrane (m) TRAIL, Rab 5B exosomal marker, actin and GM130 Golgi marker protein. J, quantification of exosomal TRAIL by ELISA in n = 10 TRAIL exosome fractions (in μg) and in lysates of originating K562 TRAIL+ cells or NGFR- K562 cells (negative control).
Figure 2.
Functionality of TRAIL exosomes. A to C, expression of TRAIL receptors. SUDHL4, INT12, and KMS11 cells were labeled with PE-conjugated mAbs against DR4, DR5, DcR1, and DcR2 or with an appropriate IgG-PE as control. Filled histograms represent the positivity for each receptor tested, lines represent IgG controls. Results show representative histograms for each cell line. D, sensitivity to sTRAIL. SUDHL4, INT12 and KMS11 cells were incubated with increasing concentrations of sTRAIL and evaluated by Annexin V/PI staining after 24 (left) and 48 hours (right) by flow cytometry. Results are shown as mean ± SEM of three independent experiments. E, sensitivity to exosomal TRAIL. SUDHL4, INT12, and KMS11 cells were incubated with increasing concentrations of exosomal TRAIL and evaluated by Annexin V/PI staining after 24 (left) and 48 hours (right) by flow cytometry. Exosomal TRAIL was determined on TRAIL exosomes by TRAIL ELISA. Results are shown as mean ± SEM of three independent experiments.
Figure 3.
Antitumor activity of TRAIL exosomes on SUDHL4 B cell lymphoma. A, caspase-3 activation. SUDHL4 cells were incubated with TRAIL exosomes (20 ng/mL exosomal TRAIL) for 24 and 48 hours and evaluated for caspase-3 activation by flow cytometry after intracellular staining. Filled histograms represent the positivity for caspase-3, dashed lines represent caspase-3 positivity in cells treated with TRAIL exosomes pre-incubated with anti-TRAIL Ab (Rik2) and lines represent caspase-3 in untreated controls. B, detection of cell death. (Continued on the following page.)
Rab 5B (Fig. 1I). The absence of Golgi protein (GM130) ascertained the purity of vesicle populations (Fig. 1I). The quantification of TRAIL in whole exosome preparations by commercial ELISA allowed to measure 1 ng TRAIL in 1 mg of TRAIL exosomes (n = 10; Fig. 1J).

Functionality of TRAIL exosomes

The proapoptotic potential of membrane TRAIL expressed by exosomes was next tested in vitro on SUDHL4 B-cell lymphoma and INT12 melanoma cells, expressing DR5 at almost 100% and DcR2 at 80% and 50%, respectively (Fig. 2A and B). The third

(Continued) Annexin V/PI staining of SUDHL4 cells after 24 and 48 hours co-culture in the presence of TRAIL exosomes (20 ng/mL exosomal TRAIL), saline or sTRAIL at 30 mg/kg/injection. B, effect on tumor growth. Left, growth curves of SUDHL4 subcutaneous nodules in SCID mice. Statistical significance was achieved by TRAIL exosome and sTRAIL treatment versus control groups (saline and NGFR exosomes) using two-way ANOVA; ***, P < 0.001; ****, P < 0.0001. Right, H&E and TUNEL staining of nodules collected from TRAIL exosomes and saline-treated mice. Images are adapted to the same scale. C, representative IHC analysis of tumors removed 24 hours after the last intravenous injection of saline, TRAIL exosomes, NGFR exosomes, or sTRAIL. Sections were stained for H&E, caspase-3, TUNEL, and Ki67. Images show the same area of serial sections stained for the above-mentioned markers.
Figure 5.
Antitumor activity of TRAIL exosomes on INT12 melanoma. A, caspase-3 activation. INT12 cells were incubated with TRAIL exosomes (15 ng/mL exosomal TRAIL) for 24 and 48 hours and evaluated for caspase-3 activation by flow cytometry after intracellular staining. Filled histograms represent the positivity for caspase-3, dashed lines represent caspase-3 positivity in cells treated with TRAIL exosomes pre-incubated with anti-TRAIL Ab (Rik2), and lines represent caspase-3 expression in untreated controls. B, DR5 expression in tumor tissues. IHC staining for DR5 on INT12 tumor sections subcutaneously grown in SCID mice (n = 2). Arrows show the positive staining on tumor vessels. (Continued on the following page.)
target included in the analysis, that is, the multiple myeloma
KMS11, expressed instead DR4 and DRβ2, both detectable in
about 30% cells (Fig. 2C). Exposure to increasing amounts of
sTRAIL showed that KMS11 was highly sensitive to sTRAIL, with
an ED50 of 15.12 and 10.77 ng/mL at 24 and 48 hours, respec-

tively (Fig. 2D). SUDHL4 reached 50% of cell death with 22 ng/

mg sTRAIL at 24 hours and with 9.33 ng/mL at 48 hours (Fig. 2D).
Thus, both the cell lines displayed a substantial increase of cell
death if the culture was prolonged to 48 hours. In contrast, INT12
melanoma cells, among the most sensitive within a panel of 10
melanoma cell lines tested (data not shown), displayed no
increased apoptosis with prolonged incubation time and never
reached 100% even at the highest sTRAIL concentration tested of
100 ng/mL (Fig. 2D).

The activity of TRAIL expressed by exosomes was tested under
the same conditions using increasing concentrations of exoso-
mal TRAIL, according to ELISA quantification. Figure 2E shows
that exosomal TRAIL was more efficient in inducing apoptosis
of SUDHL4 cells than sTRAIL, with an ED50 of 5.9 ng/mL
compared with 9.3 ng/mL for sTRAIL at 48 hours. Similarly,
in INT12 melanoma cells we observed a tendency to an
enhanced sensitivity to exosomal TRAIL with respect to sTRAIL
after 48 hours incubation, with an ED50 of 8.9 versus 19 ng/mL,
respectively. In contrast, KMS11 cells appeared to be much less
sensitive to TRAIL exosomes as compared with the soluble
molecule, both at 24 and 48 hours (Fig. 2E). This evidence
suggests a preferential interaction of exosomal TRAIL with DR5,
as KMS11 was the only cell line tested that expressed DR4 and
stained negative for DR5.

Antitumor activity of TRAIL exosomes on SUDHL4 B-cell
lymphoma

In SUDHL4 cells, apoptosis was associated with a rapid and
efficient activation of caspase-3, here shown at 24 and 48 hours
(63% and 83.6%, respectively), in the presence of 20 ng/mL exosomal
TRAIL (Fig. 3A and B). Preincubation of exosomes with TRAIL-neutralizing Ab (Rik2) completely abrogated this effect, demonstrating the specific involvement of TRAIL (Fig. 3A). In contrast, no apoptosis was detected in the pre-

cence of control NGFR exosomes (data not shown).

For in vivo testing, SCID mice were subcutaneously injected
with 2 × 106 SUDHL4 cells and, when nodules reached 200–300 mm3, they were evaluated for DR5 in vivo expression using an anti-human Ab that cross-reacts with murine TRAIL receptor. IHC analysis depicted a diffuse positivity in both
cancer cells and vessels (Fig. 3C), confirming the expression of
TRAIL receptor in the tumor microenvironment as a potential
target of proapoptotic receptor agonists (35). The dose for
in vivo treatment, that is, 200 μg exosomes, corresponding to
200 ng TRAIL, was chosen on the basis of literature data as
maximal tolerated dose (as detailed in Materials and Methods).
Of note, one single intratumor injection of TRAIL exosomes
led to measurable apoptosis (16% ± 10%) in tumor cell

susensions prepared from nodules extracted 24 hours post-
administration (Fig. 3D).

To test the therapeutic efficacy of TRAIL exosomes upon local
delivery, mice bearing SUDHL4 tumors of 200 to 300 mm3
volume were assigned to receive multiple intratumor injections
of NGFR or TRAIL exosomes. TRAIL exosome administration
led to a rapid and persisting inhibition of tumor growth
(maximal TVI 68%; Fig. 3E), with respect to the injection of
NGFR exosomes. IHC of lesions removed 24 hours after last
treatment showed that large areas of necrosis and few Ki67-
positive cells could be detected in TRAIL exosome–receiving
mice (Fig. 3F), whereas tumor lesions from NGFR exosome-
treated animals displayed high-proliferation index (Ki67) and
limited apoptosis, as depicted by activated caspase-3 expres-
sion. Caspase-3 expression was also evident at tumor vessel
level upon TRAIL exosome administration, suggesting a possi-
bile direct or indirect effect on endothelial cells, as previously
demonstrated with CD34+ TRAIL+ cells in a comparable xenograft
setting (Fig. 3G; ref. 34).

The antitumor activity of TRAIL exosomes was then ana-
alyzed upon systemic administration. To verify their actual
homing to tumor site, PKH26-labeled TRAIL exosomes were
injected intravenously in SUDHL4-bearing mice twice (Sup-
plementary Fig. S2). Confocal microscopy showed that red
fluorescently labeled cancer cells could be detected in tumor
lesions and analysis of ex vivo tumor cell suspensions revealed
the presence of Annexin V–positive cells (23.3% ± 3.4%; Sup-
plementary Fig. S2).

Systemic treatment of SUDHL4-bearing mice (Fig. 4A)
induced a rapid and progressive inhibition of tumor growth
in mice receiving TRAIL exosomes or sTRAIL, reaching 58%
reduction in tumor size at the end of treatment (Fig. 4B, left).
sTRAIL, here administered at the effective dose of 30 mg/kg/in-
jection, provided comparable results (Fig. 4B, left), although
it should be pointed out that this dose (600 μg/injection) was
remarkably higher than the TRAIL content of exosomes
(200 ng/injection). Conversely, NGFR exosomes did not influ-
ence tumor growth with respect to saline treated animals.
TUNEL staining of tumor nodules removed 24 hours after the
fourth treatment depicted large areas of necrosis covering
almost 50% of the lesion in animals receiving TRAIL exosomes,
but not in controls (Fig. 4B, right). Corroborative results were
obtained by IHC staining of tumor lesions for caspase-3 and
Ki67 (Fig. 4C).

Antitumor activity of TRAIL exosomes on INT12 melanoma

TRAIL exosomes induced TRAIL-dependent caspase-3 activa-
tion in 56% and 54% of INT12 cells after 24 or 48 hours,
respectively (Fig. 5A). DR5 expression detected by flow
cytometry was confirmed by IHC of tumor nodules from
xenotransplanted SCID mice (2 × 106 INT12 cells injected
subcutaneously), showing a consistent positivity of tumor
cells and tumor vessels (Fig. 5B). Intratumor injection of
Figure 6. 
Antitumor activity of TRAIL exosomes on KMS11 multiple myeloma. A, detection of cell death. Annexin V/PI staining of KMS11 cells after 24 and 48 hours coculture in the presence of TRAIL exosomes (200 ng/mL exosomal TRAIL). B, DR5 expression on tumor vessels. IHC staining of KMS11 tumor sections for DR5 (n = 2). The positivity was confined to endothelial vessel forming cells (arrows). C, intratumor treatment. KMS11-bearing mice received 4 treatments, every 48 hours, of TRAIL exosomes (exosomal TRAIL 200 ng/injection), sTRAIL (200 ng/injection), sTRAIL (300 μg/injection), or saline. (Continued on the following page.)
TRAIL exosomes (4 × 200 µg/injection every 48 hours) into INT12 melanoma nodules (100 mm³) mediated a significant reduction of TV (maximal TVI 51%; Fig. 5C), with respect to NGFR exosome–treated mice. This tumor kinetics was confirmed by IHC, depicting necrotic and caspase-3–positive areas extended also to tumor vessels, in TRAIL exosomes, but not NGFR exosome–treated lesions (Fig. 5D).

Systemic treatment gave similar histologic results as intratumor treatment, with large necrotic areas for mice receiving TRAIL exosomes in contrast with intact tissue in control mice (NGFR exosomes and saline, Fig. 5E). However, this scenario was not associated with a statistically significant inhibition of tumor growth, although a reduction of TV could be observed upon administration of TRAIL exosomes, as shown by the volume ratios at end versus start of treatment, with respect to the controls (NGFR exosomes and saline; Fig. 5F).

**Antitumor activity of TRAIL exosomes on KMS11 multiple myeloma**

KMS11 cells showed poor sensitivity to TRAIL exosomes in vitro (Fig. 2), even if we were able to measure about 40% of cell death by increasing the dose of exosomal TRAIL to up to 200 ng/mL (Fig. 6A).

In vivo, IHC staining of KMS11 tumor nodules confirmed the negativity for DR5 expression detected in vitro (Fig. 2), although the receptor was instead detectable on tumor vessels (Fig. 6B). Intratumor treatment of SCID mice bearing KMS11 nodules was performed according to the described schedule of 4 injections every 48 hours and included exosomal TRAIL at 200 µg/injection (corresponding to 200 ng TRAIL), sTRAIL at 200 ng/injection for comparison and sTRAIL at the effective dose of 300 µg/injection. Monitoring of tumor size revealed that a growth arrest could be detected only in animals receiving sTRAIL at the higher dose of 300 µg (data not shown). Nodules removed from these mice showed reduced size, high levels of necrosis hematoxylin and eosin (H&E and TUNEL; Fig. 6C) and cell death (80% ± 10% PI⁻; Fig. 6D). In lesions from mice receiving TRAIL exosomes, we could also observe increased areas of necrosis (H&E and TUNEL; Fig. 6C) together with augmented levels of dead cells (30% ± 10% PI⁻) (Fig. 6D). In contrast, no major change with respect to controls was detected in lesions from mice receiving sTRAIL at the exosome-equivalent dose of 200 ng (Fig. 6C and D), suggesting a higher efficacy of TRAIL exosomes in the induction of tumor apoptosis when injected locally.

Systemic administration of TRAIL exosomes did not induce any significant impact on tumor growth (data not shown), with only marginal increase of overall tumor necrosis detected by histologic analysis in mice treated with TRAIL exosomes, with respect to NGFR exosomes or saline (Fig. 6E and F, top). Interestingly, in lesions from mice receiving TRAIL exosomes we could observe significant perivascular necrosis (Fig. 6E and F, bottom).

**Discussion**

Herein, we depict the strategy for the delivery of functional TRAIL to sensitive cancers via genetically engineered exosomes. Our report shows that cells, modified to express TRAIL, can produce exosomes that incorporate the proapoptotic ligand in their membranes in an active form. TRAIL exosomes displayed a significant killing activity in vitro and in vivo, in local and systemic treatment approaches, although therapeutic efficacy varied in the different tumor models analyzed.

Thanks to the ability to shuttle their cargo and cross biologic barriers, EVs are recently being exploited as drug delivery vehicles in several diseases, including cancer. We sought to generate exosomes expressing high levels of functional TRAIL, to combine the advantage of a transmembrane conformation with nanovesicular structures for systemic delivery (11). K562 cells transduced with a human lentiviral vector were chosen as exosome producers, for their resistance to TRAIL-mediated apoptosis, the ability to grow at large scale level in vitro and the approved use for human application (16–18). Nevertheless, other donor cells, such as CD34 from healthy volunteers and different transfection tools (i.e., AdenoTRAIL vectors; refs. 34, 39), produced in our hands comparable exosomes (Supplementary Fig. S3), proving a broad applicability of the exosomal TRAIL approach.

Exosomes released by lenti-TRAIL K562 cells displayed a rather homogeneous structure and size (140 nm), and remarkable levels of TRAIL protein on their surface, as clearly depicted by immunoelectronmicroscopy. Once incubated with TRAIL-susceptible cells, they triggered rapid caspase-3–mediated cell death, indicating the ability of exosome-embedded TRAIL to efficiently crosslink its cognate receptor and initiate the apoptotic cascade. Usually the interaction of exosomes and cells can be of different nature, depending not only on the exosome surface composition but also on the type of target cell. In fact, exosomes interact through receptor-ligand docking, direct fusion, or endocytosis and are thereby taken up by the recipient cells. Our results, showing that apoptosis induced by TRAIL exosomes was completely abrogated by neutralization with TRAIL, Ab, suggest that the proapoptotic activity of TRAIL exosomes relies principally on a surface-to-surface interaction of TRAIL with its cognate receptor. Interestingly, the activity of exosomal TRAIL, but not sTRAIL tested for comparison, appeared to be superior in target cells expressing DR5 (SUDHL4 and INT12), with respect to those expressing DR4 (KMS11 cells). This evidence suggests that DR4 might harbor a conformational structure less suitable to interact with TRAIL embedded in nanosized-membrane particles.

(Continued.) Animals were sacrificed 24 hours after the last treatment and sections analyzed by IHC (representative images of H&E and TUNEL staining are shown). Images are adapted to the same scale. D, Annexin V/PI staining of tumor cell suspensions (n = 10) prepared ex vivo from nodules collected after the end of intratumor injections. E, systemic treatment of KMS11-bearing animals. KMS11-bearing mice received 4 intravenous treatments, every 48 hours, of TRAIL exosomes (exosomal TRAIL 200 µg/injection), NGFR exosomes (200 µg/injection) or saline (n = 5–7, saline and mice receiving NGFR exosomes; n = 10 animals receiving TRAIL exosomes). H&E staining of representative sections of tumors extracted after the end of treatment. F, quantification of necrotic areas. Graphs show tumor necrosis (top) and perivascular necrosis (bottom) quantified in tumor sections of animals for each group (saline, TRAIL exosomes, and NGFR exosomes). Statistical significance was achieved by TRAIL exosomes versus NGFR exosomes and saline using the Student t test; *, P < 0.05; **, P < 0.01; NS, not significant.
In vivo administration of TRAIL exosomes led to clear signs of antitumor activity in the three tumor models here analyzed. Local multiple treatments were associated with a significant inhibition of tumor growth, paralleled by remarkable caspase-3 activation and necrosis. These data indicate a potential suitability of our approach for intratumor therapy, particularly in melanoma where the strategy of achieving disease control through local injection of proapoptotic agents (e.g., oncolytic viruses) has been recently approved by the FDA (40).

The systemic administration of TRAIL exosomes, leading to detectable but undoubtedly inferior homing to tumor site, also determined evident antitumor effects. However, only the highly sensitive SUDHL4 tumor was remarkably affected by the treatment, whereas no significant impact on the growth of INT12 melanoma and KMS11 myeloma could be observed, in spite of the signs of necrosis and vessel damage detected by histologic analysis. These latter results could be explained by the evidence that exosomes homing to tumor site represent only minor fractions of those administered, which are instead largely sequestered by the major organs (33). Indeed, a pharmacokinetic study performed with Near-Infrared (NIR)–labeled or unlabeled TRAIL exosomes revealed that injected vesicles were almost immediately cleared from the blood and principally localized in the liver, lungs, and spleen, being detectable subsequently also in kidneys and bone marrow (Supplementary Fig. S4).

At this regard, we must underline that an impact of the xenogeneic nature of TRAIL exosomes on the observed treatment efficacy cannot be ruled out in our experimental setting. Hence, studies in syngeneic models are in progress to confirm a potential clinical translatable nature of our approach. In addition, the homing properties of TRAIL exosomes could be improved by inserting tumor-specific receptors or ligands, or applying strategies to avoid their clearance by macrophages (41, 42). TRAIL-mediated tumor apoptosis in immunocompetent mice would also allow engaging systemic immunity, ideally promoting an amplified antitumor effect (43, 44). Importantly, these experiments would shed light on the potential toxicity generated by systemic administration of TRAIL exosomes.

Exosomes are acknowledged to bear advantages above synthetic nanovesicles for in vivo drug delivery, mostly related to the high stability in body fluids and their properties of "natural delivery system" (45–47). Furthermore, their elevated elasticity in terms of molecular manipulation makes exosomes more appealing than for instance liposomes, also tested for TRAIL delivery (12–14). Notably, covalently bound TRAIL carried by liposomes increased its therapeutic potential with respect to the recombinant soluble counterpart, sustaining our system of exosomes released by their donor cells with "natural" membrane TRAIL (48). Indeed, in addition to molecules for homing improvement, proteins or genetic material like miRNAs could also be cargoed into TRAIL exosomes to concomitantly overcome TRAIL resistance directly at tumor site.

Another interesting strategy is represented by combining TRAIL exosomes with emerging anticancer natural compounds like piperlongumine, to increase DR5 expression and thereby sensitivity to TRAIL-mediated apoptosis (49). Obviously, it must be mentioned that exosomes, as likely independent entities, mediate a broad array of functions specific of the originating cells and in cancer they often promote disease progression (50). At this regard, we would like to underline that no major protumor effect was instead observed in the mouse models used in this study (Fig. 4B).

In summary, the delivery of TRAIL to sensitive cancers by exosomes appears as an attractive and efficient therapeutic approach, particularly for local treatment. TRAIL exosomes can be easily produced in large amounts and stored before administration. They could be combined with chemotherapeutics, small molecules, or natural compounds, aimed at augmenting TRAIL sensitivity by inducing death receptor expression, or loaded with drugs and genetic material to be delivered to cancer cells through uptake process.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: L. Rivoltini, A.M. Gianni, M.P. Colombo, V. Huber
Development of methodology: L. Rivoltini, P. Squarcina, A. Villa, B. Vergani, M. Bürdek, B. Bianchi
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Rivoltini, C. Chiidoni, M. Tortoreto, A. Villa, B. Vergani, L. Botti, I. Arioni, G. Mauri, B. Bianchi, L. Cantone, V. Bollati, N. Zaffaroni
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Chiidoni, A. Villa, M. Bürdek, B. Bianchi, P. Della Mina, N. Zaffaroni
Writing, review, and/or revision of the manuscript: L. Rivoltini, L. Cantone, N. Zaffaroni, V. Huber
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P. Squarcina, A. Cova
Study supervision: A.M. Gianni, V. Huber
Other (performed molecular experiments): E. Vergani

Grant Support
This work was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC); grant number: MCO-9998. M. Bürdek was supported by a grant from the German Research Foundation (DFG Forschungsstipendium GZ: BI 2677/1-1).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 3, 2015; revised February 16, 2016; accepted February 20, 2016; published OnlineFirst March 4, 2016.

References
TRAIL-Armed Exosomes as a Novel Antitumor Therapy


TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Licia Rivoltini, Claudia Chiodoni, Paola Squarcina, et al.


Updated version
Access the most recent version of this article at:

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2016/03/04/1078-0432.CCR-15-2170.DC1

Cited articles
This article cites 49 articles, 8 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/22/14/3499.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.